CellVoyant, a Bristol, UK-based spinout from the University of Bristol, has secured £7.6 million in seed funding.
SaaS Investors
The round was led by Octopus Ventures, with participation from Horizons Ventures, Air Street Capital, and Verve Ventures.
Founded in 2007, Octopus Ventures is a venture capital firm based in London, United Kingdom. The firm prefers to invest in the United Kingdom and European-based companies operating in the health tech, climate, people & talent, bio, fintech, deep tech, consumer, and b2b software sectors.
CellVoyant Use of Funds
The company will use the funding to grow the team, expand infrastructure, and further develop its technology for commercialization.
About CellVoyant
Founded in 2021, CellVoyant is an AI-first biotechnology company with a mission to create novel stem cell-based therapies for chronic diseases. The company employs AI imaging technology to help researchers efficiently manufacture stem cell therapies. Its AI imaging platforms enable real-time tracking and monitoring of stem cells' reactions and evolution without the need for sample removal.
Funding Details
Company: CellVoyant Technology Ltd.
Raised: £7.6M
Round: Seed Round
Funding Month: January 2024
Lead Investors: Octopus Ventures
Additional Investors: Horizons Ventures, Air Street Capital, and Verve Ventures
Company Website: https://cellvoyant.com/
Software Category: AI Biotech
Source: https://sifted.eu/articles/ai-biotech-cellvoyant-raise